Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Saudi Arabia flag Saudi Arabia · Delayed Price · Currency is SAR
156.00
+0.50 (0.32%)
Apr 28, 2026, 3:10 PM AST
3.31%
Market Cap 10.92B
Revenue (ttm) 1.50B
Net Income (ttm) 463.80M
Shares Out 70.00M
EPS (ttm) 6.63
PE Ratio 23.54
Forward PE n/a
Dividend 4.00 (2.57%)
Ex-Dividend Date Mar 2, 2026
Volume 21,365
Average Volume 56,704
Open 156.00
Previous Close 155.50
Day's Range 155.10 - 156.80
52-Week Range 125.00 - 183.80
Beta 0.27
RSI 66.84
Earnings Date Apr 30, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceutica... [Read more]

Sector Healthcare
Founded 1994
Country Saudi Arabia
Stock Exchange Saudi Stock Exchange
Ticker Symbol 4015
Full Company Profile

Financial Performance

In 2025, TADAWUL:4015's revenue was 1.50 billion, an increase of 13.82% compared to the previous year's 1.32 billion. Earnings were 463.80 million, an increase of 30.09%.

Financial Statements

News

There is no news available yet.